Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Lund University · Skåne University Hospital · +23 more institutions
Abstract
Global implementation of blood tests for Alzheimer's disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden (n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181.…
Citation impact
- FWCI
- 127.73
- Percentile
- 100%
- References
- 30
Authors
30- SPSebastian PalmqvistCorresponding
Lund University, Skåne University Hospital
- NWNoëlle Warmenhoven
Lund University
- FAFederica Anastasi
Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, Hospital Del Mar, Centre for Genomic Regulation
- APAndrea Pilotto
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia
- SJShorena Janelidze
Lund University
Topics & keywords
- Medicine
- Biomarker
- Primary care
- Cohort
- Internal medicine
- Receiver operating characteristic
- Secondary care
- Disease